Microparticles (MP) are cell-derived fragments known to be increased in the blood of patients with acute coronary syndromes. We aimed to assess, in ST elevation myocardial infarction (STEMI), the systemic and local (in the culprit coronary artery) levels of platelet-derived MP (PMP, CD42+CD31+) and endothelial-derived MP (EMP, CD422CD31+) and their relation to indexes of microvascular obstruction (MVO).
Introduction
Primary percutaneous coronary intervention (pPCI) is the preferred reperfusion strategy in patients presenting with ST elevation myocardial infarction (STEMI). 1 The outcome of pPCI, however, continues to be unsatisfactory in more than one-third of the patients because of microvascular obstruction (MVO) occurring, despite a patent coronary artery. 2 Distal embolization of atherothrombotic debris during PCI is one of the key events in the pathogenesis of MVO, 3 leading to mechanical occlusion of microvessels and to activation of coagulation and inflammation pathways. 4 Interestingly, a large amount of the material retrieved by aspiration devices measures ,60 mm in size. 5 Thus, besides angiographically visible, macroembolization, microembolization of particles with dimensions less than the average pore size of basket filters (100 mm) is likely to be clinically relevant. 6, 7 Microparticles (MP) are small membrane vesicles (0.5 -1 mm) released by various cells upon activation or apoptosis, with procoagulant properties, 8 significantly increased in the systemic blood of STEMI patients. 9 In consideration of their small size and of their high concentration in growing thrombus and in atherosclerotic plaques, 10 they might contribute to microembolization 11 ; but this has never been convincingly demonstrated.
In our study, in STEMI patients undergoing pPCI, we explored the systemic and local concentration of platelet-derived MP (PMP) and endothelial-derived MP (EMP) and their relation with MVO defined through multiple angiographic and electrocardiographic (ECG) indexes. Moreover, we aimed to assess whether angiographically defined thrombus burden may affect the possible relationship between MP levels and MVO.
Methods Patients
Seventy-eight consecutive STEMI patients treated by pPCI including thrombus aspiration were prospectively enrolled, from a total of 180 pPCIs performed at our institution between June 2009 and December 2010. All patients were admitted to our coronary care unit with chest pain, new persistent ST-segment elevation, cardiac troponin T (TnT) elevation, and/or new regional wall motion abnormalities. 12 Exclusion criteria for all patients were: age .80 years, infarction secondary to ischaemia due to an imbalance of O 2 supply and demand, previous ECG abnormalities that could prevent the recognition of ST-segment shift, recent or chronic infective or inflammatory diseases, malignancy, surgery or trauma in the previous month, or coronary anatomy judged unfavourable for thrombus aspiration. Patients undergoing rescue PCI were also excluded (see Supplementary material online, Figure S1 ). All patients received aspirin (250 mg i.v.) and clopidogrel (600 or 300 mg if already on clopidogrel) plus standard heparin to maintain an activated clotting time of .300 s. Glycoprotein IIb/IIIa antagonists were administered at physicians' discretion after thrombus aspiration. Local Ethics Committee approved the study and all patients signed an informed consent. All procedures were followed in accordance with the ethical standards of the responsible committees on human experimentation and with the Helsinki Declaration.
Angiographic analysis of thrombotic burden
Thrombus score (TS) was used as an angiographic index of thrombotic burden at the site of the culprit coronary artery. Intracoronary thrombus was identified and scored in five grades as previously described, after the passage of a standard coronary 0.014 in. guidewire. 13 For further details, see Supplementary material online, Methods.
Angiographic indexes of microvascular obstruction and ST resolution
The indexes considered for reperfusion assessment at the end of pPCI were: thrombolysis in myocardial infarction (TIMI) flow grade, corrected TIMI frame count (cTFC), myocardial blush grade (MBG), and quantitative blush evaluator (QuBE) for angiographic (epicardial and myocardial) reperfusion and ST resolution (SSTR) for ECG reperfusion. Corrected TIMI frame count was calculated at the end of pPCI as described previously. 14 All patients also underwent MBG assessment: at the end of each pPCI procedure, a long final run at 30 frames/s was acquired in specific projections in order to minimize superimposition of the perfusion territories of the different arteries.
Myocardial blush grade was defined as previously described and scored as MBG 0 -3. 15 To evaluate myocardial reperfusion as a continuous variable, we also assessed QuBE score, a more reproducible angiographic measure of microvascular perfusion, recently introduced by Dutch investigators 16, 17 and validated against cardiovascular magnetic resonance for MVO detection by our group. 18 Finally, all enrolled patients had paired ECGs recorded at baseline and at 90 min after pPCI for SSTR calculation. 19 For further details, see Supplementary material online, Methods.
Blood sampling and microparticle level measurement
Two main types of MP were measured: PMP and EMP. Two blood samples were sequentially obtained: one from the guiding catheter in the ascending aorta before culprit coronary artery cannulation and another from the culprit coronary artery during pPCI. Briefly, a 6 Fr coronary guiding catheter was placed in the ascending aorta. The catheter was carefully flushed, the first 10 mL of blood was discarded, and a sample of 30 mL was collected. Subsequently, a 0.014 in. guidewire was placed to the distal part of the artery and a monorail aspiration catheter (Diver CE Max, Invatec Medtronic, Roncadelle, Italy) was advanced to the thrombus. A second 30 mL blood sample was collected during slow, multiple passes through the thrombotic material. Primary percutaneous coronary intervention was then performed according to the standard techniques. After collection, intracoronary blood was filtered to remove plaque fragments and cellular macroaggregates using a BD Falcon 40 mm pore-sized cell strainer (BD, Italy, Milan), included in the Diver CE Max kit. The assessment of haematocrit (%) and white blood cells count (n/mL) was performed on coronary and aortic blood sample using routine methodology. Cardiac TnT was quantitatively determined by the chemical chemistry laboratory at Gemelli Hospital (Rome, Italy) using a one-step electroimmunoassay based on electrochemiluminescence technology (Elecsys 2010, Roche), with a lower detection limit of 0.01 ng/mL.
For technical details on cytofluorimetric MP measurements, see Figure 1 and Supplementary material online, Methods.
Statistical analysis
All variables were expressed as mean + standard deviation (SD) or as median accompanied by inter-quartile range (IQR), as appropriate. Microparticle levels and cTFC and QuBE values are shown as median and IQR, as the Shapiro-Wilk test showed that the data were not normally distributed but positively skewed. In order to allow the use of parametric techniques, common logarithmic transformation was applied. After transformation, paired sample t-test was used to compare intracoronary and aortic MP level values. Frequencies were compared with x 2 or Fisher's test, as appropriate.
Analysis of variance (ANOVA) with P for linear trend calculation was used to assess the relationship between MP levels and MBG and TS, with Scheffe's post hoc comparisons. Correlations between MP levels and cTFC and QuBE values were assessed by calculating Pearson's R correlation coefficient.
To assess whether MP levels were independently associated with MVO, defined by angiographic criteria as post-procedure TIMI flow ,3 or as MBG , 2 in the presence of TIMI flow 3 and by ECG criteria as SSTR , 70%, a multivariate logistic regression model was used for estimating the odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs 
Results

Patients' characteristics
Clinical characteristics of enrolled patients are summarized in Table 1 . The majority of patients were in Killip's class I-II at admission, and about one-third presented with a total ischaemic time longer than 6 h. As expected, patients with low MBG presented with a worse Killip's class and had a significantly longer total ischaemic time. Corrected TIMI frame count and QuBE values ranged from a minimum of 11 and 1 to a maximum of 100 and 25.7, respectively.
Microparticle levels in aortic and intracoronary samples
All MP levels (n/mL) were significantly higher in intracoronary than in aortic blood TS (P: 0.034 for overall ANOVA and ,0.001 for linear trend), but no significant differences, in terms of aortic EMP levels among TS classes, were observed at post hoc analysis.
No correlation was observed between PMP levels (both intracoronary and aortic) and platelet count (R: 20.08, P: 0.48 for intracoronary PMP and R: 20.07, P: 0.52 for aortic PMP).
Microparticle levels and indexes of myocardial reperfusion
Among MP, intracoronary PMP only were related to SSTR, with significantly higher levels in patients with absent SSTR (Figure 3) . In contrast, aortic PMP and EMP were not significantly related to MBG. Interestingly, when epicardial and myocardial perfusion were expressed as continuous variables, not only intracoronary PMP and EMP were significantly related to both cTFC (R: 0.5, P , 0.001 for PMP and R: 0.30, P: 0.05 for EMP) and QuBE values (R: 20.65, P , 0.001 for PMP and R: 20.34, P: 0.003 for EMP), but also aortic PMP resulted significantly related to both cTFC (R: 0.46, P , 0.001) and QuBE values (R: 20.42, P , 0.001) (see Supplementary material online, Figure S2 ).
When Pearson's correlation coefficients were compared, however, intracoronary PMP exhibited a significantly stronger relationship than aortic PMP with QuBE score (z: 22.01; P: 0.02).
Intracoronary PMP and EMP were also significantly related to MVO expressed as a combination of SSTR (complete: .70% or incomplete: ,70%) and MBG (≥2 or ,2), being higher in the case of incomplete SSTR and MBG , 2 [2519.8 (1040.1 - (Figure 4) .
In higher TS classes, the presence of combined angiographic and ECG MVO (MBG , 2 and absent SSTR) was significantly related to higher levels of intracoronary PMP and EMP (see Supplementary material online, Figure S3 and Results).
Multivariate analysis
Variables associated with the occurrence of angiographic MVO at binary logistic multivariate analysis were total ischaemic time (OR 2.30, 95% CI 1.34-3.86, P ¼ 0.007), LAD as culprit vessel (OR 3.45, 95% CI 1.09-11.07), Killip's class (OR 2.21, 95% CI 1.05-6.30, P ¼ 0.04), and intracoronary PMP (OR 1.10, 95% CI 1.02-1.4, P: 0.006) ( Table 2) . Factors related to ECG MVO occurrence were total ischaemic time (OR 1.08, 95% CI 1.01-3.24, P ¼ 0.05), Killip's class (OR 1.89, 95% CI 1.05 -3.71, P ¼ 0.05), and intracoronary PMP (OR 1.01, 95% CI 1.01-1.02, P ¼ 0.01) ( Table 3) .
At multivariate linear regression analysis, only total ischemic time (b: 20.24; P: 0.01) and intracoronary PMP (b: 20.73; P: 0.003) were independently associated with QuBE score, explaining 57% of its variability (R 2 : 0.57; P: 0.001) ( Table 4) .
Discussion
The main and novel findings of our study are as follows: (i) PMP and EMP levels are significantly higher in blood samples collected from the culprit coronary artery than in samples collected in the ascending aorta in STEMI patients, suggesting local production; (ii) intracoronary PMP and EMP, and aortic PMP levels, are related to culprit coronary artery thrombotic burden; (iii) among MP, intracoronary PMP levels only are related to SSTR; (iv) intracoronary PMP and EMP levels are significantly related to MBG; (v) intracoronary PMP and EMP, but also aortic PMP levels, are significantly related to myocardial perfusion when continuous variables such as cTFC and QuBE are used. Intracoronary PMP, however, more strongly related to angiographic indexes of MVO than aortic PMP; (vi) multivariate models show that intracoronary PMP levels, together with total ischaemic time, Killip's class, and LAD as culprit vessel, are independently related to angiographic and ECG MVO. The notion that PMP and EMP are increased in the systemic blood of acute coronary syndrome (ACS) patients is not new. 9 Our study additionally reports that in STEMI, intracoronary MP levels are significantly higher than aortic levels, confirming a previous case series of 12 patients. 20 This result is supported by a large array of data indicating a direct role of several types of MP in thrombus generation. 21 Indeed, by carrying phosphatidylserine on their surface, MP may bear active tissue factor (TF), the main activator of coagulative cascade. 22 Platelet-derived microparticles and EMP, in particular, have a special role in coagulation cascade and thrombus generation, beyond the mere surface expression of TF.
In particular, EMP were found to express a large amount of Von Willebrand factor multimers which promote and stabilize platelet aggregates, 23 while PMP participate in thrombus development by a TF-independent pathway, promoting thrombus propagation once coagulation has been triggered by TF exposure. 24 This would help to understand how besides intracoronary PMP, aortic PMP levels also were related to TS, supporting the notion of a systemically increased platelet reactivity related to a more severe thrombotic coronary occlusion. 25 The main novelty of our study, however, is represented by the evidence of a significant direct relationship of MP with ECG and angiographic indexes of MVO after pPCI. This correlation is significantly stronger for intracoronary than for aortic MP, suggesting an involvement of MP released at the site of the culprit stenosis in the pathogenesis of MVO, perhaps favouring thrombus generation in coronary microcirculation. 26 This notion is further confirmed by the observation that intracoronary PMP are related to the presence of ECG and angiographic MVO independently from the thrombotic burden. Distal embolization of the atherothrombotic material during PCI has already been identified as an important mechanism leading to aortic PMP with cTFC and QuBE further supports the hypothesis of a systemic in addition to a local component in MVO pathogenesis. 28 Our data are in line with those by Botto et al., 30 who observed a higher platelet-leukocytes aggregation index and an higher co-aggregate volume in intracoronary blood of STEMI patients undergoing pPCI. In their study, however, platelet-leukocyte aggregates were only supposed to be involved in MVO pathogenesis, as reperfusion success was not assessed. Microparticles could act in MVO pathogenesis in two ways: (i) mechanically occluding small capillaries, especially when agglomerated with platelet and neutrophils; (ii) enhancing thrombus formation at the site of coronary microvascular damage. Indeed, previous studies have reported how MP can directly affect cellular physiology by carrying several mediators on their surface or in their inside. 31 Tissue factor is one of these molecules, and, in an animal model, intracoronary TF infusion was by itself able to cause MVO. 4 In a small study, Ko et al. reported higher levels of soluble TF in blood samples from the culprit coronary artery than in samples from the femoral artery. 32 Even if limited by the relatively small sample size, the multivariate analysis in our study gives supportive evidence of a direct relationship of MP with MVO, since intracoronary PMP levels were independently related to MVO together with more conventional factors, such as total ischaemic time and Killip's class. Until now, attention has been focused on MP mainly as markers for early diagnosis of ACS even if the complexity of measurement methods is likely to hamper this application in clinical practice. Our data, even if not providing a causative mechanism, might support the hypothesis of MP as active elements in distal embolization and MVO pathophysiology, thus representing a potential target for future therapeutic strategies.
Limitations
Our study has several limitations, the first being represented by the relatively small sample size. Secondly, we are aware that our study design, being clinical in nature, cannot conclusively answer pathophysiological questions regarding the causative role for MP in MVO, which could only be clarified in a controlled, ex vivo setting. As a consequence, our results should be mainly considered hypothesis-generating. Thirdly, we did not measure MP levels in the coronary sinus blood, which could have strengthened our results. However, there are ethical issues in performing transcoronary gradients in acutely ill STEMI patients. Fourthly, since we did not directly measure prothrombotic activity, or Annexin Vpositive MP, or TF-bearing MP, or monocyte-derived MP that mostly carry TF, 10 we could only suppose that MP might affect myocardial reperfusion by expression of TF on their surface. Annexin-V binding to phosphatidylserine, however, is profoundly affected by calcium concentration, which could not be controlled for when comparing systemic to intracoronary blood. 33 Lastly, the inferential power of the reported multivariate analyses must be considered limited due to the risk of overfitting.
Conclusions
Microparticle levels are significantly higher in blood samples from the culprit coronary artery than in those obtained from aortic circulation and they are significantly related to TS, an angiographic index expressing the thrombotic burden at the site of the culprit stenosis. Moreover, intracoronary MP levels, in particular, are directly related to different indexes of MVO in STEMI patients after pPCI. Thus, our data suggest that MP might play a direct and an active role in the pathogenesis of MVO and might represent a new potential therapeutic target.
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